FEED

#4995
ENvue Medical, Inc. - Common Stock
0.3 4 USD
-0.08%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.34
0.34
Intervallo Annuale
0.29
6.09
Variazione giornaliera
-8.11%
Variazione Mensile
+9.68%
Variazione di 6 mesi
-82.65%
Variazione Annuale
-92.64%
Chiusura Precedente
0.3 7
Open
0.3 4
Minimo
0.3 4
Massimo
0.3 4
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Envue Medical, Inc. quarterly report, Q2 FY2026
10-Q
Quarterly report, Q1 FY2026
Envue Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Envue Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Envue Medical, Inc. current report, Q4 FY2025
8-K

Envue Medical, Inc. current report, 16 November 2020

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on November 16, 2020. The filing serves to announce the company's financial results for the third fiscal quarter ended September 30, 2020. The registrant is an emerging growth company incorporated in Delaware, with its common stock (Symbol: NAOV) trading on the Nasdaq Capital Market.

Key Financial Metrics

The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the input text.

Material Changes

The filing text does not provide specific details on material changes versus the prior comparable period. It only indicates that the results for the quarter ended September 30, 2020, have been announced via a press release.

Guidance, Outlook, and Risks

The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in this report, including the referenced press release, is being furnished pursuant to Item 2.02 and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that section.

Investor Verification Checklist

  • Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 16, 2020), as they are not present in this summary text.
  • Confirm the company name is NanoVibronix, Inc. (NAOV), noting the discrepancy with the "Envue Medical, Inc." label in the request metadata.
  • Review the full press release for any forward-looking statements or guidance that may have been issued alongside the quarterly results.
  • Check the company's status as an emerging growth company for potential differences in financial reporting standards.